---
title: CDMO Daily News — July 28, 2026
slug: daily-news-2026-07-28-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: July 28 CDMO daily: Laurus Labs CDMO Revenue Surges 67% on Small Molecule API Demand; AsymBio Breaks Ground on Shanghai Fengxian R&D Building for Biologics…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-07-28-cdmo
published_at: 2026-07-28T00:00:28.146Z
last_updated: 2026-07-28T00:02:00.611Z
---

### [Laurus Labs](/companies/lauruslabs) CDMO Revenue Surges 67% on Small Molecule API Demand
- [Laurus Labs](/companies/lauruslabs)' CDMO business grew 67% year-over-year to ₹870 crore ($99.4M) in Q1 FY2027, driven by small molecule APIs rising 69% to ₹835 crore ($95.4M).
- The company secured land in Visakhapatnam for a new manufacturing facility and in-licensed two antibody-drug conjugates, signaling capacity expansion and portfolio diversification.
- Consolidated net profit more than doubled to ₹361.99 crore ($41.4M) with EBITDA margin improving to 31.8% due to higher capacity utilization.

**Operational Impact**

[Laurus Labs](/companies/lauruslabs)' accelerating small molecule CDMO capacity and new Visakhapatnam facility acquisition expand late-stage clinical and commercial API supply options for sponsors seeking alternatives to congested contract manufacturers.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/laurus-labs-posts-67-cdmo-growth-driven-by-small-molecule-demand)*

---

### [AsymBio](/companies/asymbio) Breaks Ground on Shanghai Fengxian R&D Building for Biologics Development
- [AsymBio](/companies/asymbio) is constructing an eight-story, 20,000-square-meter R&D building at its Shanghai Fengxian site, with completion targeted for H2 2027.
- The facility will support cell line development, upstream/downstream process development, ADC conjugation, drug product development, and analytical services, positioned adjacent to clinical and commercial manufacturing lines.
- The building will house AccPCC, an AI-enabled platform designed to accelerate development timelines from lead compound to preclinical candidate selection and integrate early R&D with CMC and manufacturing scale-up.

**Operational Impact**

[AsymBio](/companies/asymbio)'s Fengxian R&D expansion adds integrated biologics development capacity in APAC, enabling tighter CMC-to-manufacturing alignment and potentially reducing project timelines for sponsors developing antibodies and ADCs in the region.

*Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/asymbio-breaks-ground-on-new-fengxian-rd-building)*

---

### [Asymchem](/companies/asymchem)'s Jilin Carbapenem API Facility Clears First FDA Pre-Approval Inspection
- [Asymchem](/companies/asymchem)'s DH2 carbapenem API facility in Jilin, China passed its first USFDA Pre-Approval Inspection in April–June 2026, supporting commercial continuous-flow manufacturing.
- The facility, commissioned in 2020, features in-house continuous ozonolysis technology at tonnage scale and supplies custom carbapenem intermediates for clinical and commercial programs.
- Asymchem operates 200+ annual customer audits and has completed over 100 regulatory inspections globally, applying Quality by Design frameworks across its CDMO network.

**Operational Impact**

[Asymchem](/companies/asymchem)'s DH2 facility PAI clearance establishes a validated carbapenem API source with continuous-flow capacity, reducing supply-chain risk for CDMO customers developing or commercializing carbapenem-based therapeutics.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/asymchems-carbapenem-api-facility-passes-first-usfda-pre-approval-inspection)*

## References

1. [PharmaSource RSS — Laurus Labs CDMO Revenue Surges 67% on Small Molecule API Demand](https://pharmasource.global/content/news/cdmo-news/laurus-labs-posts-67-cdmo-growth-driven-by-small-molecule-demand)
2. [Contract Pharma Breaking News RSS — AsymBio Breaks Ground on Shanghai Fengxian R&D Building for Biologics Development](https://www.contractpharma.com/breaking-news/asymbio-breaks-ground-on-new-fengxian-rd-building)
3. [PharmaSource RSS — Asymchem's Jilin Carbapenem API Facility Clears First FDA Pre-Approval Inspection](https://pharmasource.global/content/news/cdmo-news/asymchems-carbapenem-api-facility-passes-first-usfda-pre-approval-inspection)

Source: https://www.cdmo.directory/posts/daily-news-2026-07-28-cdmo